GLP-1s Lower Heart Failure Risk by 40% in HFpEF Patients

A study published in JAMA found that patients with heart failure with⁤ preserved ejection fraction ⁤(HFpEF) who started semaglutide or tirzepatide experienced⁣ a 40% reduction in hospitalization for HF ⁤or all-cause mortality.

The research utilized 3 US claims databases with patient data, including demographics, diagnoses, procedures, and medications. Cohorts compared semaglutide to sitagliptin, tirzepatide to⁤ sitagliptin, and tirzepatide to semaglutide, with additional cohorts created using expanded eligibility criteria.

The study population included‌ over 1.6 million individuals,with subsets meeting criteria emulating the STEP-HFpEF and SUMMIT clinical trials. The mean age of participants ranged from 66.7 to 70.8 ⁢years, and approximately 53-54% were female. Mean BMI ranged from 36.6 to 40.2.